Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled time : 22:00 save search
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
DMAC | $2.5 3.31% 3.2% 7.4K
|
Health Technology
|
| O: 4.43%
H: 0.0%
C: 0.0%
dm199 first stroke treatment for trial therapeutics
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is VitalLack of early symptom improvement is not predictive of final responder status
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
STIM | $3.76 -2.59% -2.66% 21K
|
Health Technology
|
| O: 1.18%
H: 4.28%
C: 1.17%
publication treatment
Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa
Published: 2024-03-01 (Crawled : 22:00) - biospace.com/
AADI | $1.79 -2.72% -2.79% 110K
|
Manufacturing
|
| O: 1.02%
H: 0.0%
C: 0.0%
fyarro bioscience publication treatment
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
Published: 2024-02-23 (Crawled : 22:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
LEGN | News | $45.205 -4.73% -4.97% 1.1M
|
Health Technology
|
| O: 2.07%
H: 5.02%
C: 4.92%
carvykti chmp biotech positive treatment therapy
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
Published: 2024-02-01 (Crawled : 22:00) - globenewswire.com
CABA | $12.94 -2.85% -2.94% 760K
|
Health Technology
|
| O: -2.09%
H: 12.16%
C: 9.33%
caba-201 fda drug granted treatment designation
Proniras Corporation Secures New Series B Financing and Names New Board Members to Support Phase 1 Study of Novel Treatment for Opiate Withdrawal
Published: 2024-02-01 (Crawled : 22:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.27%
H: 2.04%
C: 2.02%
corporation series treatment study
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
Published: 2024-01-29 (Crawled : 22:00) - globenewswire.com
CDTX | News | $11.94 16.49% 14.15% 170K
|
Health Technology
|
| O: 1.04%
H: 3.96%
C: -3.25%
approval treatment candidiasis rezzayo therapeutics
City Office REIT Announces Tax Treatment of 2023 Distributions
Published: 2024-01-26 (Crawled : 22:00) - prnewswire.com
CIO | $4.57 -1.08% 0.0% 160K
|
Finance
| Email alert
Add to watchlist
treatment city
Digital Realty Announces Tax Treatment of 2023 Dividends
Published: 2024-01-25 (Crawled : 22:00) - prnewswire.com
DLR | $140.61 1.5% 0.0% 1.6M
|
Finance
|
| O: 0.48%
H: 1.22%
C: 0.23%
dividends treatment realty
Sun Communities, Inc. Announces Tax Treatment of 2023 Distributions
Published: 2024-01-19 (Crawled : 22:00) - globenewswire.com
SUI 4 | $120.3 0.22% 0.0% 600K
|
Finance
| Email alert
Add to watchlist
treatment
First Industrial Realty Trust Reports Tax Treatment of Common Stock Distributions
Published: 2024-01-19 (Crawled : 22:00) - prnewswire.com
FR | $46.03 -0.95% 0.0% 1.2M
|
Finance
| Email alert
Add to watchlist
first treatment realty trust
Broadstone Net Lease Announces Tax Treatment of 2023 Dividends
Published: 2024-01-19 (Crawled : 22:00) - broadstone.com
BNL | $14.44 -0.76% 0.0% 970K
|
Finance
| Email alert
Add to watchlist
dividends treatment
GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
Published: 2024-01-18 (Crawled : 22:00) - globenewswire.com
GHRS | $11.01 -2.57% -2.63% 45K
|
Manufacturing
|
| O: -1.24%
H: 8.99%
C: 5.22%
patent depression treatment research grant
Park Hotels & Resorts Announces Tax Treatment of 2023 Dividends
Published: 2024-01-16 (Crawled : 22:00) - globenewswire.com
PK | $16.79 0.36% 0.0% 1.7M
|
Finance
|
| O: -1.82%
H: 2.36%
C: 1.53%
dividends treatment hotels
Lyme Disease Treatment Market is Expected to Showcase Significant Growth by 2032, Assesses DelveInsight | Key Companies - Pfizer, ModernaTX, Tarsus Pharmaceuticals, Valneva, Cortene
Published: 2024-01-15 (Crawled : 22:00) - prnewswire.com
DERM | $3.425 -3.25% -3.36% 60K
|
|
| O: 1.45%
H: 8.38%
C: 6.95%
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: 0.0%
H: 2.08%
C: -1.46%
TARS | $32.77 -2.79% -2.87% 320K
|
Health Technology
|
| O: 0.14%
H: 2.58%
C: 2.17%
disease companies expected treatment key growth market
Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsight
Published: 2024-01-15 (Crawled : 22:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.15%
H: 0.59%
C: -1.45%
drug treatment heart market
Achondroplasia Treatment Drug Market to Register Positive Growth by 2032, Assesses DelveInsight | Key Companies in the Market - Ascendis Pharma, QED Therapeutics (BridgeBio), Novartis, Sanofi, RIBOMIC
Published: 2024-01-09 (Crawled : 22:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.13%
H: 0.0%
C: 0.0%
drug companies achondroplasia positive treatment key therapeutics growth market
Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function
Published: 2023-12-20 (Crawled : 22:00) - prnewswire.com
CALT | $18.5 1.65% 1.62% 1.5K
|
Health Technology
|
| O: 14.59%
H: 6.13%
C: -1.09%
tarpeyo fda nephropathy kidney approval treatment therapeutics
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
Published: 2023-12-15 (Crawled : 22:00) - globenewswire.com
ARQT | $8.76 0.23% 0.23% 1.8M
|
Health Technology
| Email alert
Add to watchlist
zoryve fda dermatitis treatment
Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Published: 2023-12-15 (Crawled : 22:00) - biospace.com/
VRTX | $400.66 -1.05% -1.06% 790K
|
Health Technology
|
| O: 0.38%
H: 0.84%
C: 0.62%
first disease chmp positive cell treatment
Gainers vs Losers
| 65% | 35% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 210M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
ILAG | $0.51 6.03% 29.06% 430K
|
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.